Synonym
Dexclamol HCl; AY24,169; AY-24,169; AY 24,169; AY24169; AY-24169; AY 24169; Dexclamol hydrochloride
IUPAC/Chemical Name
1H-Benzo(6,7)cyclohepta(1,2,3-de)pyrido(2,1-a)isoquinolin-3-ol, 2,3,4,4a,8,9,13b,14-octahydro-3-(1-methylethyl)-, hydrochloride, (3alpha,4aalpha,13bbeta)-(+)-
InChi Key
UTDKIRCKPWMOAD-JRPKOJKMSA-N
InChi Code
InChI=1S/C24H31NO.ClH/c1-16(2)24(26)13-12-19-22-9-5-6-14-25(22)15-20-18-8-4-3-7-17(18)10-11-21(24)23(19)20;/h3,7,10,15-16,18,26H,4-6,8-9,11-14H2,1-2H3;1H/t18?,24-;/m1./s1
SMILES Code
O[C@]1(C(C)C)C(CC=C2C3CCC=C2)=C4C3=CN5C(CCCC5)=C4CC1.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
385.98
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Jaramilio J. A study of the effects of dexclamol as the neuroleptic component in neuroleptanaesthesia. Br J Anaesth. 1976 Dec;48(12):1149-55. doi: 10.1093/bja/48.12.1149. PMID: 1023951.
2: Pugsley TA, Lippmann W. Dexclamol: effects on catecholamine metabolism and demonstration of stereochemical specificity of antagonism of central adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol. 1976 Nov;295(2):117-22. doi: 10.1007/BF00499442. PMID: 11420.
3: Liljefors T, Bøgesø KP. Conformational analysis and structural comparisons of (1R,3S)-(+)- and (1S,3R)-(-)-tefludazine, (S)-(+)- and (R)-(-)-octoclothepin, and (+)-dexclamol in relation to dopamine receptor antagonism and amine-uptake inhibition. J Med Chem. 1988 Feb;31(2):306-12. doi: 10.1021/jm00397a006. PMID: 2892932.
4: Liu ST, Hurwitz A. Effect of enantiomeric purity on solubility determination of dexclamol hydrochloride. J Pharm Sci. 1978 May;67(5):636-8. doi: 10.1002/jps.2600670516. PMID: 641798.
5: Jaramillo J. Dexclamol, a candidate for neuroleptanalgesia. Can J Physiol Pharmacol. 1976 Apr;54(2):140-5. doi: 10.1139/y76-022. PMID: 1276987.
6: Moereels H, Tollenaere JP. A comparison between the conformation of dexclamol and the tricyclic and butyrophenone type dopamine antagonists. Life Sci. 1978 Aug 7;23(5):459-63. doi: 10.1016/0024-3205(78)90153-4. PMID: 29188.
7: Olson GL, Cheung HC, Morgan KD, Blount JF, Todaro L, Berger L, Davidson AB, Boff E. A dopamine receptor model and its application in the design of a new class of rigid pyrrolo[2,3-g]isoquinoline antipsychotics. J Med Chem. 1981 Sep;24(9):1026-34. doi: 10.1021/jm00141a002. PMID: 6116805.
8: Seeman P, Westman K, Protiva M, Jílek J, Jain PC, Saxena AK, Anand N, Humber L, Philipp A. Neuroleptic receptors: stereoselectivity for neuroleptic enantiomers. Eur J Pharmacol. 1979 Jun 15;56(3):247-51. doi: 10.1016/0014-2999(79)90177-8. PMID: 38971.
9: Sarges R, Howard HR, Donahue KM, Welch WM, Dominy BW, Weissman A, Koe BK, Bordner J. Neuroleptic activity of chiral trans-hexahydro-gamma-carbolines. J Med Chem. 1986 Jan;29(1):8-19. doi: 10.1021/jm00151a002. Erratum in: J Med Chem 1986 May;29(5):876. PMID: 3941416.
